{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=8+Gy&page=3", "query": { "intervention": "8 Gy", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 347, "total_pages": 35, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=8+Gy&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=8+Gy&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-01T01:36:31.315Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03872505", "title": "Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Cedars-Sinai Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2022-07", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2021-08-25", "last_synced_at": "2026-11-01T01:36:31.315Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03872505" }, { "nct_id": "NCT00449020", "title": "Carboplatin, Irinotecan, and Radiation Therapy Followed By Docetaxel in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 32, "start_date": "2004-01", "completion_date": "2008-01", "has_results": false, "last_update_posted_date": "2016-12-15", "last_synced_at": "2026-11-01T01:36:31.315Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00449020" }, { "nct_id": "NCT04302025", "title": "A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Alectinib", "type": "DRUG" }, { "name": "Entrectinib", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Pralsetinib", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "SBRT", "type": "DRUG" }, { "name": "Resection", "type": "PROCEDURE" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Divarasib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 99, "start_date": "2020-11-06", "completion_date": "2030-05-30", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-11-01T01:36:31.315Z", "location_count": 38, "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 28 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04302025" }, { "nct_id": "NCT03035890", "title": "Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Non Small Cell Lung Cancer Metastatic" ], "interventions": [ { "name": "Radiation", "type": "RADIATION" }, { "name": "Immuno-Therapeutic Agent", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "West Virginia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2017-01-23", "completion_date": "2022-06-30", "has_results": true, "last_update_posted_date": "2025-04-01", "last_synced_at": "2026-11-01T01:36:31.315Z", "location_count": 1, "location_summary": "Morgantown, West Virginia", "locations": [ { "city": "Morgantown", "state": "West Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03035890" }, { "nct_id": "NCT07335380", "title": "Lattice-Based Radiotherapy and Chemo-Immunotherapy for Oral Cavity Squamous Cell Carcinoma", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Oral Cavity Squamous Cell Carcinoma" ], "interventions": [ { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Lattice Radiotherapy (LRT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-04", "completion_date": "2031-03", "has_results": false, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-11-01T01:36:31.315Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07335380" }, { "nct_id": "NCT00193427", "title": "Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2004-04", "completion_date": "2008-12", "has_results": true, "last_update_posted_date": "2022-03-03", "last_synced_at": "2026-11-01T01:36:31.315Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00193427" }, { "nct_id": "NCT07552558", "title": "Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "HPV-Negative Squamous Cell Carcinoma" ], "interventions": [ { "name": "Hypofractionated Stereotactic Body Radiotherapy (SBRT)", "type": "RADIATION" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Ficerafusp alfa", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "BIOLOGICAL", "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2026-09-30", "completion_date": "2033-11-30", "has_results": false, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-11-01T01:36:31.315Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07552558" }, { "nct_id": "NCT03944915", "title": "De-Escalation Therapy for Human Papillomavirus Negative Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Human Papilloma Virus", "Squamous Cell Carcinoma", "Squamous Cell Carcinoma of the Head and Neck", "HPV-Related Squamous Cell Carcinoma", "HNSCC" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" }, { "name": "Hydroxyurea Pill", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "Filgrastim Injection", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2019-08-26", "completion_date": "2023-11-01", "has_results": true, "last_update_posted_date": "2025-05-11", "last_synced_at": "2026-11-01T01:36:31.315Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03944915" }, { "nct_id": "NCT03311555", "title": "A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Apalutamide", "type": "DRUG" }, { "name": "Androgen deprivation", "type": "DRUG" }, { "name": "Salvage radiation therapy", "type": "RADIATION" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Andrew J. Armstrong, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 39, "start_date": "2018-03-28", "completion_date": "2022-12-22", "has_results": true, "last_update_posted_date": "2024-03-19", "last_synced_at": "2026-11-01T01:36:31.315Z", "location_count": 5, "location_summary": "Omaha, Nebraska • New York, New York • Cary, North Carolina + 2 more", "locations": [ { "city": "Omaha", "state": "Nebraska" }, { "city": "New York", "state": "New York" }, { "city": "Cary", "state": "North Carolina" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03311555" }, { "nct_id": "NCT00505921", "title": "Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Campath-1H", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "GM-CSF", "type": "DRUG" }, { "name": "BCNU", "type": "DRUG" }, { "name": "Stem Cell Transplant", "type": "DRUG" }, { "name": "Preparative Regimen for Allogenic Stem Cell Transplantation", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Campath", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Low dose total body irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": 27, "start_date": "2003-03", "completion_date": "2009-11", "has_results": true, "last_update_posted_date": "2011-11-16", "last_synced_at": "2026-11-01T01:36:31.315Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00505921" } ] }